FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $32.08M
• Dividend Yield: N/A
• Average Volume (3M): 165.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 13
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 37,735,300
• 10 Day Avg. Volume: 147,569
• 30 Day Avg. Volume: 165,030
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 1311.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

FibroBiologics, Inc. is in a challenging financial position typical of early-stage biotech firms, with no revenue and significant reliance on external financing. The technical indicators suggest a bearish market sentiment, and the valuation metrics reflect the company's current lack of profitability. The absence of earnings call data and corporate events leaves the stock with a low overall score.

Positive Factors

Clinical Trials

The company has highlighted anticipated initiation of the Australian Phase 1/2 trial evaluating CYWC628 in DFU, while trial completion is expected by year-end, coinciding with awaited early results in DFU.

Market Opportunity

Chronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.

Therapeutic Potential

Fibroblast therapies offer a differentiated therapeutic benefit, addressing unmet needs in connective tissue formation and wound healing.

Negative Factors

Financial Performance

Fibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.

Funding Concerns

The company is expected to be funded into mid-2025.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its fibroblast-based therapies. The company may earn income through licensing agreements, partnerships with pharmaceutical companies, and the sale of its therapeutic products once they receive regulatory approval. Additionally, FibroBiologics might secure funding through research grants, equity investments, and collaborations with academic institutions or healthcare organizations. These partnerships and investments support the company's research and development efforts, facilitating the advancement of its innovative therapies to the market.

FibroBiologics, Inc. Financial Statement Overview

Summary

FibroBiologics, Inc. faces significant financial challenges with no revenue generation and increasing operational losses. Reliance on external funding raises sustainability concerns, though liquidity has improved slightly.

Income Statement

FibroBiologics, Inc. has consistently reported zero revenue, indicating no sales activity or market penetration. The company shows increasing losses over the years, with negative EBIT and Net Income margins worsening. This reflects high operational costs without corresponding revenue generation, a significant concern for financial sustainability.

Balance Sheet

The company has a weak equity position, with stockholders' equity improving from negative to positive but remaining low relative to liabilities. The debt-to-equity ratio is volatile due to fluctuating equity, posing significant financial risk. However, the increase in total assets and cash reserves signals some improvement in liquidity.

Cash Flow

Operating cash flow remains negative, indicating persistent cash burn. Free cash flow is also negative, driven by operational losses. Cash inflows from financing activities have been substantial, suggesting reliance on external funding. This raises concerns about long-term cash sustainability without revenue.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-407.00K	-437.00K	-94.00K	0.00	0.00
	EBIT
-12.51M	-8.89M	-4.47M	-1.58M	-1.17M
	EBITDA
-17.21M	-15.90M	-4.37M	-1.58M	0.00
	Net Income Common Stockholders
-17.78M	-16.48M	-5.12M	-1.58M	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
407.00K	9.16M	2.27M	407.00K	0.00
	Total Assets
0.00	11.82M	4.82M	468.00K	0.00
	Total Debt
0.00	1.75M	7.52M	1.52M	0.00
	Net Debt
0.00	-7.42M	5.26M	1.12M	0.00
	Total Liabilities
1.29M	10.57M	8.82M	1.76M	0.00
	Stockholders Equity
-1.29M	1.25M	-4.00M	-1.29M	0.00
Cash Flow		Free Cash Flow
-10.52M	-6.90M	-4.07M	-1.41M	-1.17M
	Operating Cash Flow
-10.43M	-6.40M	-4.07M	-1.41M	-1.17M
	Investing Cash Flow
-87.00K	-495.00K	0.00	0.00	0.00
	Financing Cash Flow
7.58M	13.79M	5.92M	1.82M	1.17M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.20, and below the 200-day MA of 2.50, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 31.17 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$4.01B	-18.30	-14.99%	6.62%	25.52%	-80.16%
BPMC	52 Neutral	$5.24B	―	-31.26%	―	104.04%	87.80%
RCUS	49 Neutral	$768.41M	―	-59.77%	―	120.51%	25.37%
FATE	42 Neutral	$105.39M	―	-54.21%	―	-78.55%	-0.92%
FGEN	42 Neutral	$26.53M	―	60.38%	―	5.59%	83.59%
KPTI	36 Underperform	$34.00M	―	41.08%	―	-0.55%	49.85%
FBLG	23 Underperform	$32.08M	―	-559.73%	―	―	―

FibroBiologics, Inc. Corporate Events

FibroBiologics Approves Executive Bonuses for 2024

On January 23, 2025, FibroBiologics, Inc. announced that its Compensation Committee and Board of Directors approved the 2024 fiscal year annual incentive bonuses for its executive officers. The updated Summary Compensation Table reveals the total compensation, including bonuses, stock options, and other earnings for the fiscal year ended December 31, 2024. Notably, a bonus of $75,000 was approved for Robert E. Hoffman, the Interim Chief Financial Officer.